The type of TET2 mutations and the specific exons involved in this study were also largely similar to those seen in patients with MPN or SM. 2, 3 Because of the relatively small number of patients included in this study, it is important not to overplay the observed disease-specific mutational frequencies. Furthermore, accurate interpretation of TET2 mutational frequency requires accounting for age; in our earlier report involving patients with BCR-ABL-negative classic MPN (n ¼ 239), 2 overall mutational frequency was 23% in patients X60 years of age versus 4% in younger patients (Po0.0001).
The above-mentioned observations raise several questions: (i) Considering the ubiquitous nature of mutant TET2 in myeloid malignancies, is it possible that it is also present in lymphoid or other neoplasms? (ii) In instances where mutant TET2 coexists with other mutations, does it predate or postdate their emergence? (iii) Within the context of a specific disease, does the presence of mutant TET2 affect phenotype, prognosis or treatment response? (iv) Is mutant TET2, in those who carry the mutation, a better indicator of clonal response to treatment? (v) What exactly is the pathogenetic contribution of mutant TET2 in myeloid malignancies? It is relatively easy to address the first four questions, but we encourage patience before making any clinical associations until one sees a consistent pattern across studies from different centers. The question that is both most important and difficult to address concerns the precise pathogenetical contribution of mutant TET2 in myeloid neoplasms, especially in view of its occurrence across different molecular profiles.
The type of TET2 mutations seen so far are mostly frameshift or nonsense, and are therefore inactivating. Furthermore, Delhommeau et al. 1 have shown that both copies of the gene were affected in a subset of TET2-mutated MPN patients, and that mutant TET2 was associated with loss-of-heterozygosity/somatic deletion at its 4q24 chromosomal location, suggesting a tumor suppressor function for the wild-type allele. They also showed the occurrence of mutant TET2 in both JAK2V617F-positive and negative clones from otherwise JAK2V617F-positive MPN patients, suggesting that TET2 mutations antedated JAK2V617F during the evolution of the malignant clone, at least in certain instances. In the presence of mutant TET2, as opposed to its absence, the coexisting JAK2V617F-positive clone constituted a higher proportion of the CD34 þ /CD38À cell fraction and showed enhanced engrafting in NOD-SCID mice. Taken together, these observations would suggest that TET2 mutations, although ubiquitous, are not simply passenger mutations and that their acquisition by the malignant clone might enhance its stem cell-like properties without necessarily affecting its differentiating capacity. Additional laboratory studies are needed to further clarify the biological consequence of these mutations. Therapies that are targeted to the molecular genetic defect of malignancies have proven more successful than conventional chemotherapeutic approaches. [1] [2] [3] [4] A broad application of this strategy will require a detailed understanding of the genetic lesions involved in oncogenesis. Tyrosine kinases constitute a gene family of 91 members that play a critical role in numerous cellular processes, and aberrant regulation of tyrosine kinase activity has been observed in numerous types of malignancies. 5 One malignancy in which tyrosine kinases are abnormally
Letters to the Editor regulated is acute myeloid leukemia (AML). Several reports have shown that signal transducer and activator of transcription 5 (STAT5) is phosphorylated in blast cells from at least 70% of patients with AML. 6-8 STAT5 phosphorylation is tightly controlled by tyrosine kinase signaling networks; hence this suggests the presence of aberrantly active, mutated tyrosine kinases in these patients.
To better understand the genetic lesions underlying this aberrant tyrosine kinase activity, we and others have recently performed large-scale sequencing screens of selected genes or entire cancer genomes. [9] [10] [11] [12] This process revealed many nonsynonymous sequence variants; however, functional characterization of most of these mutations failed to produce evidence supporting an oncogenic role for these mutations. We hypothesized that some of these 'passenger' mutations may have relevance to oncogenesis and that functional characterization by expression in standard murine cell lines failed due to the absence of a proper signaling machinery for the ectopically expressed human proteins. We here show that the expression of a mutated gene found in an individual AML patient, TEK G743A , does confer hypersensitivity to growth factor as well as increased basal phosphorylation of mitogenic signaling pathways in the human AML cell line, UT-7, but not in the murine pro-B cell line, Ba/F3. These data suggest that other 'passenger' mutations identified in large-scale sequencing screens may contribute to leukemogenesis and that the choice of cellular setting for functional follow-up studies is critical for the proper understanding of these mutant genes.
We identified a novel, non-synonymous sequence variant in TEK (G743A) in a patient with AML. 10 This mutant allele was not observed in DNA from 96 normal individuals. Although two other gain-of-function mutant TEK alleles have been reported earlier, 13, 14 neither of these mutations were associated with a leukemic phenotype; thus, we wanted to assess the contribution of this mutant allele to leukemogenesis. We initially introduced the ectopic expression of TEK WT or TEK G743A into the murine pro-B-cell setting, Ba/F3. To determine whether the mutant allele of TEK could confer growth factor independence or hypersensitivity to Ba/F3 cells, we cultured each cell line in varying doses of interleukin-3 and performed a cell viability assay after 5 days. The cells expressing TEK G743A exhibited identical growth curves compared with those expressing TEK WT , indicating that this mutant allele of TEK did not enhance growth or viability of Ba/F3 cells under cytokine-deprived circumstances (Figure 1a) . We next hypothesized that although this mutant allele of TEK may not confer hypersensitivity to interleukin-3, it may exhibit hypersensitivity to its ligand, angiopoietin-1 (ANG-1). Thus, we performed a time course of stimulation with ANG-1 in both TEK WT-and TEK
G743A
-expressing Ba/F3 cells and subjected whole-cell lysates to immunoblotting for phosphotyrosine to examine the stimulation of tyrosine kinase signaling networks. Interestingly, neither TEK WT-nor TEK
-expressing cells exhibited any increase in phosphotyrosine levels at any time point following stimulation with ANG-1 (Figure 1b) . To rationalize this finding, we hypothesized that ectopic expression of TEK in this murine pro-B-cell setting may not provide the proper signaling network for TEK activity. To test this hypothesis, we next evaluated mutant and wild-type TEK in the setting of a human AML cell line.
We created UT-7 cells stably expressing TEK WT and TEK G743A . To assess the ability of the mutant TEK allele to confer growth factor hypersensitivity in this new setting of UT-7 cells, we cultured each cell line in varying doses of granulocyte macrophage-colony stimulating factor and performed a cell viability assay after 5 days. Interestingly, UT-7 cells expressing TEK G743A exhibited significantly increased growth and viability at submaximal doses of granulocyte macrophage-colony stimulating factor compared with UT-7 cells expressing TEK WT , indicating that this mutant allele of TEK can enhance growth and viability of cells under cytokine-deprived circumstances in the setting of a human AML cell line (Figure 2a) . To determine whether this ectopically expressed TEK protein now has the ability to respond to exogenous ANG-1 stimulation, we next performed a time course of stimulation with ANG-1 identical to that performed in Ba/F3 cells. In this new setting, TEK WTexpressing cells could now be observed to exhibit increases in phosphotyrosine levels at 30 and 60 min following ANG-1 stimulation, indicating that TEK kinase activity was being activated by ligand in this human AML cell line setting. Consistent with a model of increased activity of the TEK G743A allele, unstimulated cells that were expressing this mutant allele exhibited phosphotyrosine levels that were analogous to the level observed in TEK WT cells at the maximal phosphotyrosine time points of 30 and 60 min post-stimulation (Figure 2b ). To directly compare the differences in phosphorylation of mitogenic signaling pathways in TEK WT versus TEK G743A UT-7 cells, WT or TEK G743A were serum-starved overnight followed by a time course of stimulation with angiopoietin-1 at 200 ng/ml. Cells were lysed at the indicated times and whole-cell lysates were subjected to immunoblot analysis with antibodies specific for phosphotyrosine (4G10) or TEK.
Letters to the Editor we next performed immunoblot for phospho-STAT5 and phospho-AKT on serum-starved cells. In addition to detectable increases in global phosphotyrosine in TEK G743A compared with TEK WT , we also observed that both STAT5 and AKT exhibited increased phosphorylation in cells expressing the mutant allele compared with those expressing wild type (Figure 2c) .
Several recent studies have undertaken large-scale sequencing screens of cancer genomes in an effort to identify the genetic lesions contributing to the genesis of cancer. [9] [10] [11] [12] New improvements in sequencing technology promise to accelerate the pace of this data accrual. 15, 16 Although these screens have identified numerous genetic abnormalities, the majority of these mutations have either remained uncharacterized or have not exhibited evidence of contributing to oncogenesis. This may be partly due to the fact that most characterization of mutant alleles has taken place in cell line settings that may not be relevant to the disease from which the mutant allele was identified. Murine cell lines as well as cell lines from a divergent cell lineage may not have the appropriate signaling networks for proper function of all ectopically expressed human proteins. Here we show that a mutant allele in the angiopoietin receptor, TEK, found in an AML patient exhibits characteristics consistent with a role for leukemogenesis when expressed in the setting of a human AML cell line, but not in a murine pro-B cell line. In addition to establishing the mutant allele, TEK G743A , as a rare contributing factor in AML, these data also indicate that numerous other mutant alleles that were previously thought to be 'passenger' mutations may, in fact, play a role in oncogenesis. As wholegenome sequencing data become more readily available, the choice of cellular setting for characterization of these mutant alleles will be important for a complete understanding of the genetics of cancer.
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